SecBot SecBot
DEFA14A ·Filed Apr 22, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-170335
Proxy solicitation materials
Actionable Insight • Neutral

Monitor for any shareholder dissent on executive compensation, though this routine filing suggests business as usual.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$55.41
T+0 close · Apr 22, 2026 · via day close
Latest settled
+19.18%
T+60 · $66.04
Vs SPY
+14.17%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $55.41entry
  2. T+1 · 7mo ago −0.31%α −1.09% · $55.24
  3. T+5 · 7mo ago +0.61%α −0.86% · $55.75
  4. T+20 · 6mo ago −1.32%α −5.95% · $54.68
  5. T+60 · 4mo ago +19.18%α +14.17% · $66.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the re-election of eight directors, approval of executive compensation, and reappointment of its auditor. This routine filing follows a recent amendment to its equity incentive plan, indicating ongoing governance activities.

Key Financial Metrics

Vote
director election
Meeting
2025-06-04
Seats Contested
8

Key Facts

  • Filing is a definitive proxy statement (DEFA14A) for the 2025 annual meeting
  • Proposes re-election of eight directors including Dawn Svoronos, Gillian Cannon, and Justin Gover
  • Seeks approval of executive compensation and reappointment of PwC as auditor
  • Follows recent 8-K filing amending the equity incentive plan

Financial Impact

Routine governance filing with no immediate financial impact

governanceexecutive compensation

Risk Factors

  • Potential shareholder dissent on executive compensation
  • Board continuity risk if any directors are not re-elected

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-170335
Document: 0001193125-26-170335-index-headers.html0001193125-26-170335
Document: 0001193125-26-170335-index.html0001193125-26-170335
Document: 0001193125-26-170335.txt0001193125-26-170335

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 9h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 22, 2026